Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent's NDA Filing for Humira Biosimilar Accepted in China

publication date: Nov 13, 2018

Innovent Biologics of Suzhou reported that China regulators have accepted its filing of a new drug application for IBI303, a biosimilar to Humira (adalimumab). It is Innovent's second NDA accepted by the NMPA -- the first is its anti-PD-L1 candidate (IBI308). IBI303 is a recombinant human anti-TNF-α monoclonal antibody aimed at ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis. Innovent said IBI303 will offer a high-quality and affordable alternative to branded Humira in China. More details....

Stock Symbol: (HK: 1801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.